Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.010
Sell
RSI(14)
45.386
Neutral
STOCH(KDJ)(9,3,3)
37.940
Buy
ATR(14)
0.078
Low Volatility
CCI(14)
-47.146
Neutral
Williams %R
55.102
Sell
TRIX(12,20)
-0.828
Sell
StochRSI(14)
100.000
Buy
Autolus Therapeutics PLC
AUTL1.420USD
+0.100+7.58%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
377.92MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Autolus Therapeutics PLC
Currency: USD Updated: 2026-02-06Key Insights
Autolus Therapeutics PLC's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 44 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 8.99.In the medium term, the stock price is expected to remain stable.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Autolus Therapeutics PLC's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
Autolus Therapeutics PLC Highlights
StrengthsRisks
Autolus Therapeutics plc is a United Kingdom-based early commercial-stage biopharmaceutical company developing programmed T cell therapies for the treatment of cancer and autoimmune diseases. The Company has an approved commercial product, AUCATZYL, for the treatment of adult patients with r/r B-ALL. Using a suite of proprietary and modular T cell programming technologies, it is also developing five programs in seven hematological and solid tumor indications and one autoimmune indication. It is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and attack and eliminate these cells. Its product pipeline includes obe-cel (ALLCAR19), obe-cel (CAROUSEL), AUTO1/22 (CARPALL), AUTO4 (LibrA T1), AUTO6 (MAGNETO), AUTO5, AUTO8 (MCARTY) and AUTO9. AUTO4 and AUTO5 are two programmed T cell therapies for the treatment of peripheral T-cell lymphoma targeting TRBC 1 and TRBC 2.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 59.12% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 10.12M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 10.12M.
Overvalued
The company’s latest PE is -1.69, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 194.47M shares, increasing 0.07% quarter-over-quarter.
Held by Invesco
Star Investor Invesco holds 38.05K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.62.
Analyst Rating
Based on
11
analysts
Buy
Current Rating
8.990
Target Price
+581.06%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-02-06The current financial score of Autolus Therapeutics PLC is 7.30, ranking 126 out of 392 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is average.
Score
Financials
5.22
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.86
Operational Efficiency
6.21
Growth Potential
9.79
Shareholder Returns
7.44
Autolus Therapeutics PLC's Company Valuation
Currency: USD Updated: 2026-02-06The current valuation score of Autolus Therapeutics PLC is 7.88, ranking 76 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -1.69, which is -34.08% below the recent high of -1.12 and -298.32% above the recent low of -6.75.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 44/392
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-02-06The current earnings forecast score of Autolus Therapeutics PLC is 8.73, ranking 66 out of 392 in the Biotechnology & Medical Research industry. The average price target is 10.00, with a high of 13.00 and a low of 5.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
11
analysts
Buy
Current Rating
8.990
Target Price
+581.06%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
173
Total
6
Median
8
Average
Company name
Ratings
Analysts
Autolus Therapeutics PLC
AUTL
11
Biogen Inc
BIIB
36
Amgen Inc
AMGN
35
Vertex Pharmaceuticals Inc
VRTX
33
Eli Lilly and Co
LLY
33
Gilead Sciences Inc
GILD
31
1
2
3
...
35
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-02-06The current price momentum score of Autolus Therapeutics PLC is 6.56, ranking 224 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 1.82 and the support level at 1.16, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
1.376
Buy
MA10
1.394
Buy
MA20
1.437
Sell
MA50
1.563
Sell
MA100
1.525
Sell
MA200
1.718
Sell
Institutional Confidence
Currency: USD Updated: 2026-02-06The current institutional shareholding score of Autolus Therapeutics PLC is 10.00, ranking 1 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 90.55%, representing a quarter-over-quarter decrease of 3.81%. The largest institutional shareholder is James Simons, holding a total of 4.88M shares, representing 1.83% of shares outstanding, with 208.15% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Risk Assessment
Currency: USD Updated: 2026-02-06The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Autolus Therapeutics PLC is 3.55, ranking 137 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 1.99. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
1.99
VaR
+6.96%
240-Day Maximum Drawdown
+54.10%
240-Day Volatility
+81.15%
Return
Best Daily Return
60 days
+13.64%
120 days
+18.12%
5 years
+35.47%
Worst Daily Return
60 days
-17.13%
120 days
-17.13%
5 years
-38.13%
Sharpe Ratio
60 days
+0.27
120 days
-0.45
5 years
+0.01
Risk Assessment
Maximum Drawdown
240 days
+54.10%
3 years
+84.36%
5 years
+85.68%
Return-to-Drawdown Ratio
240 days
-0.45
3 years
-0.09
5 years
-0.18
Skewness
240 days
+0.39
3 years
+0.60
5 years
+0.51
Volatility
Realised Volatility
240 days
+81.15%
5 years
+86.53%
Standardised True Range
240 days
+8.80%
5 years
+17.88%
Downside Risk-Adjusted Return
120 days
-84.99%
240 days
-84.99%
Maximum Daily Upside Volatility
60 days
+71.74%
Maximum Daily Downside Volatility
60 days
+61.03%
Liquidity
Average Turnover Rate
60 days
+0.83%
120 days
+0.80%
5 years
--
Turnover Deviation
20 days
+62.28%
60 days
+28.45%
120 days
+24.08%
Peer Comparison
Biotechnology & Medical Research
Autolus Therapeutics PLC
AUTL
7.42 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Alkermes Plc
ALKS
8.60 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ascendis Pharma A/S
ASND
8.53 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ionis Pharmaceuticals Inc
IONS
8.38 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
IQVIA Holdings Inc
IQV
8.37 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
BioCryst Pharmaceuticals Inc
BCRX
8.17 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
